GlaxoSmithKline CEO Emma Walmsley has reportedly received a pay cut of 14 per cent after the company missed an internal profit target for sales of routine vaccinations against other diseases.
According the pharmaceutical giant’s annual report, Ms Walmsley’s total remuneration for 2020 came in at seven million pounds (€8.2 million).
The cut, according to comments by Non-Executive Director Urs Rohner in the report, partly reflected a missed internal profit target for biopharmaceuticals, mainly due to lockdowns stopping people from receiving routine vaccinations which cut into the CEO’s bonus.
Ms Walmsley was appointed CEO in 2017, and has made great strides in the company’s restructuring efforts, as it works to split its consumer and pharmaceutical businesses.
GlaxoSmithKline has been among the frontrunners in the effort to develop COVID-19 vaccines and treatments, with the company’s offering, which was developed in conjunction with the University of Oxford, having been approved for use in over 50 countries.
Last month, pharmaceutical chiefs came under fire as EU leaders prioritised the acceleration of COVID-19 vaccination rollouts, with pharmaceutical companies being pressed to abide by delivery commitments.
Kenneth Farrugia: Financial crime prevention ‘extends to the national dimension’
He argues that protecting individual organisations is no longer sufficient, given the broader implications financial crime can have for a ...
Nathan Farrugia and Mireille Muscat set up leadership peer network
'Leadership can become surprisingly isolating long before someone reaches the C-suite'.
Corinthia CEO Simon Naudi: Hotel awards reflect teams’ ‘standards, efforts and creativity’
Corinthia hotels secured a series of accolades from Condé Nast Traveler and the Michelin Guide.
Global tourism summit an ‘extraordinary opportunity for Malta’ – MTA CEO
Over 200 of the world's leading travel & tourism CEOs are set to gather in Valletta.
